Cite

HARVARD Citation

    Pinyol, R. et al. (2019). Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 68 (6), pp. 1065-1075. [Online]. 
  
Back to record